Scientists unleash engineered immune cells and Cancer-Killing virus in First-of-Its-Kind trial
NCT ID NCT03740256
First seen Feb 06, 2026 · Last updated Apr 08, 2026 · Updated 12 times
Summary
This early-stage trial is testing the safety of a new two-part treatment for people with advanced HER2-positive solid tumors, such as breast, lung, or gastric cancer. First, a specially designed virus is injected directly into one tumor to help alert the immune system. A few days later, patients receive an infusion of their own immune cells, which have been engineered in a lab to find and attack HER2-positive cancer cells. The main goal is to find a safe dose and see how well the body tolerates this combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor St. Luke's Medical Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.